Therapeutics of Alzheimer's disease: Past, present and future
The DOI matches its Crossref record; 406 of the 406 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 406
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149 · cited 1×
“Apolipoprotein E 34 (ApoE 34) increases passage of Ab from blood to brain (Martel et al., 1997).”
BackgroundRole of melatonin in Alzheimer-like neurodegeneration1
Wang, J., & Wang, Z. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00260.x · Cited by 148
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710823105 · Cited by 146
Vilaró, M. T., Cortés, R., & Mengod, G. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20447 · Cited by 142
Fisher, A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 140
Rojo, L. E., Alzate-Morales, J., Saavedra, I. N., Davies, P., & Maccioni, R. B. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1262 · Cited by 140
Promotion of transition metal-induced reactive oxygen species formation by β-amyloid
Bondy, S. C., Guo-Ross, S. X., & Truong, A. T. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00461-2 · Cited by 139
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11409 · Cited by 136
Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007) · Neurology · doi:10.1212/01.wnl.0000281847.17519.e0 · Cited by 136
Gauthier, S., Aisen, P. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., Garceau, D., Suhy, J., Oh, J., Lau, W., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0106-x · Cited by 135
Lahiri, D., Maloney, B., Riyaz Basha, M., Wen Ge, Y., & Zawia, N. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362164 · Cited by 134
Banerjee, P., Samoriski, G., & Gupta, S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081976 · Cited by 134
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133 · cited 1×
“Etazolate was safe and well tolerated in a recent trial, but the effectiveness and long term benefits are to be determined (Vellas et al., 2011).”
BackgroundImportance of the nicotinic acetylcholine receptor system in the prefrontal cortex
Wallace, T. L., & Bertrand, D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.001 · Cited by 133
Choi, S., Aid, S., Caracciolo, L., Sakura Minami, S., Niikura, T., Matsuoka, Y., Turner, R. S., Mattson, M. P., & Bosetti, F. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12059 · Cited by 132
Selenica, M., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707471 · Cited by 131
Lefèvre, G. Y., Sedek, G., Jhee, S. S., Leibowitz, M. T., Huang, H.-L., Enz, A., Maton, S., Ereshefsky, L., Pommier, F., Schmidli, H., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100242 · Cited by 130
Alzheimer's Disease: Critical Notes on the History of a Medical Concept
Ramírez‐Bermúdez, J. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.008 · Cited by 129
Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease–Like Pathology and Cognitive Decline
Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto‐Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & LaFerla, F. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.041 · Cited by 129
Colton, C. A., Vitek, M. P., Wink, D. A., Xu, Q., Cantillana, V., Previti, M. L., Van Nostrand, W. E., Weinberg, J. B., & Dawson, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601075103 · Cited by 128
Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., & Shea, T. B. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508325093 · Cited by 127
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126 · cited 1×
“A number of investigators have looked at the possible advantage of its combining memantine with AChEI in AD (Atri et al., 2013; Dantoine et al., 2006; Howard et al., 2012; Lopez et al., 2009; Porsteinsson et al., 2008; Riepe et al., 2007; Tariot et al., 2004).”
BackgroundHo, L., Chen, L. H., Wang, J., Zhao, W., Talcott, S. T., Ono, K., Teplow, D., Humala, N., Cheng, A., Percival, S. S., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0916 · Cited by 126
Treatment Strategies Targeting Amyloid -Protein
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 126
Weinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J. P. M., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_10 · Cited by 125
Pinto, T., Lanctôt, K. L., & Herrmann, N. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.003 · Cited by 125
Wahlberg, L. U., Lind, G., Almqvist, P. M., Kusk, P., Tornøe, J., Juliusson, B., Söderman, M., Selldén, E., Seiger, Å., Eriksdotter-Jönhagen, M., et al. (2012) · Journal of Neurosurgery · doi:10.3171/2012.2.jns11714 · Cited by 125
Cholinergic influences on cortical development and adult neurogenesis
Bruel‐Jungerman, E., Lucassen, P. J., & Francis, F. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.021 · Cited by 124
Atack, J. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.001 · Cited by 124
Galasko, D. R., Graff-Radford, N., May, S., Hendrix, S., Cottrell, B. A., Sagi, S. A., Mather, G., Laughlin, M., Zavitz, K. H., Swabb, E., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 123
Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study
Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C., Lyketsos, C. G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000265223.25679.2a · Cited by 122
Quinn, J. F., Kulhanek, D., Nowlin, J., Jones, R., Praticò, D., Rokach, J., & Stackman, R. W. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.023 · Cited by 122
Yoshimura, S., Morishita, R., Hayashi, K., Yamamoto, K., Nakagami, H., Kaneda, Y., Sakai, N., & Ogihara, T. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301566 · Cited by 121
Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease1
Morris, M. C., Evans, D. A., Schneider, J. A., Tangney, C. C., Bienias, J. L., & Aggarwal, N. T. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9410 · Cited by 120
Intranasal Insulin Ameliorates Tau Hyperphosphorylation in a Rat Model of Type 2 Diabetes
Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X., & Gong, C.-X. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121294 · Cited by 120
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Isaac, M. G. E. K. N., Clark, A. R., Rusted, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub3 · Cited by 120
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119
Wischik, C. M., Bentham, P., Wischik, D. J., & Seng, K. M. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.05.438 · Cited by 118
Bilikiewicz, A., & Gaus, W. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6103 · Cited by 116
Maher-Edwards, G., Zvartau-Hind, M., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 116
Martínez, E. M. G., Sanz‐Blasco, S., Karachitos, A., Bández, M. J., Fernández-Gómez, F.-J., Perez‐Alvarez, S., de Mera, R. M. M.-F., Jordán, M. J., Aguirre, N., Galindo, M. F., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.07.028 · Cited by 113
Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035277 · Cited by 113
Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A. M., Movsesyan, N., Kiyatkin, A., Rasool, S., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4672-12.2013 · Cited by 112 · cited 1×
“A few novel anti-amyloid vaccines like MER5101, Lu AF20513 have been successful in the pre-clinical studies and some candidate vaccines like ACI-24, Affitope AD-02/AD-03, UB-311 and V-950 are in different phases of development (Davtyan et al., 2013; Galimberti et al., 2013; Liu et al., 2013).”
BackgroundKhalili, M., & Hamzeh, F. (2010) · PubMed · Cited by 112
Cheng, Y., Wang, C., Lin, H.-B., Li, Y., Huang, Y., Xu, J., & Zhang, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1943-3 · Cited by 111
Dumont, M., Wille, E., Calingasan, N. Y., Tampellini, D., Williams, C., Gouras, G. K., Liby, K., Sporn, M., Flint Beal, M., & Lin, M. T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05970.x · Cited by 111
Bakchine, S., & Loft, H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13110 · Cited by 111
A Novel Inhibitor of Amyloid β (Aβ) Peptide Aggregation
McKoy, A. F., Chen, J., Schupbach, T., & Hecht, M. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348037 · Cited by 109
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004010037 · Cited by 108
Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J.-J., & Bourdeix, I. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00769.x · Cited by 106
He, P., Ouyang, X.-P., Zhou, S., Yin, W., Tang, C., Laudon, M., & Tian, S. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.04.009 · Cited by 106
β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic mice
Chang, W., Huang, X., Downs, D., Cirrito, J. R., Koelsch, G., Holtzman, D. M., Ghosh, A. K., & Tang, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-167213 · Cited by 106
Maher-Edwards, G., Dixon, R., Hunter, J., Gold, M., Hopton, G., Jacobs, G., Hunter, J., & Williams, P. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2562 · Cited by 105
Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
Imbimbo, B. P., Panza, F., Frisardi, V., Solfrizzi, V., D’Onofrio, G., Logroscino, G., Seripa, D., & Pilotto, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.550572 · Cited by 105
Park, S. H., Kim, J. H., Bae, S. S., Hong, K. W., Lee, D., Leem, J. Y., Choi, B. T., & Shin, H. K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.068 · Cited by 103
Berger-Sweeney, J. E. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00070-8 · Cited by 102
Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia
Andrieux, A., Salin, P. A., Schweitzer, A., Bégou, M., Pachoud, B., Brun, P., Gory‐Fauré, S., Kujala, P., Suaud‐Chagny, M., Höfle, G., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.048 · Cited by 100
Slotkin, T. A., Seidler, F. J., Crain, B. J., Bell, J. M., Bissette, G., & Nemeroff, C. B. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2452 · Cited by 99
Dinamarca, M. C., Ríos, J. A., & Inestrosa, N. C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00464 · Cited by 99
Methylphenidate for Apathy and Functional Status in Dementia of the Alzheimer Type
Padala, P. R., Burke, W. J., Shostrom, V., Bhatia, S. C., Wengel, S. P., POTTER, J. F., & Petty, F. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cabcf6 · Cited by 98
Friedhoff, L. T., Cullen, E. I., Geoghagen, N. S. M., & Buxbaum, J. D. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002310 · Cited by 98
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97 · cited 2×
“Apolipoproteins play prominent roles in Ab metabolism and transport (Fan et al., 2009); though they do not cross the blood brain barrier, they regulate the movement of Ab between the central nervous system and periphery (Ladu et al., 2000).”
BackgroundGilling, K. E., Jatzke, C., Hechenberger, M., & Parsons, C. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.012 · Cited by 96
5-HT7 receptors in the modulation of cognitive processes
Cifariello, A., Pompili, A., & Gasbarri, A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.012 · Cited by 94
Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 94
Oestrogen replacement therapy may improve memory functioning in the absence of APOE ε4
Burkhardt, M. S., Foster, J. K., Laws, S. M., Baker, L. D., Craft, S., Gandy, S. E., Stuckey, B. G. A., Clarnette, R., Nolan, D., Hewson-Bower, B., et al. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6302 · Cited by 94
Cholesterol and statins in Alzheimer’s disease: current controversies.
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.013 · Cited by 93
Molecular and cellular mechanisms of DNA vaccines
Coban, C., Koyama, S., Takeshita, F., Akira, S., & Ishii, K. J. (2008) · Human Vaccines · doi:10.4161/hv.4.6.6200 · Cited by 93
Farrimond, L. E., Roberts, E., & McShane, R. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000917 · Cited by 92
Cerebrolysin: A Review of its Use in Dementia
Plosker, G. L., & Gauthier, S. G. (2009) · Drugs & Aging · doi:10.2165/11203320-000000000-00000 · Cited by 89
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for alzheimer’s disease
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 89
Parachikova, A., Green, K. N., Hendrix, C., & LaFerla, F. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014015 · Cited by 87 · cited 1×
“utilizing combination to create nutrient cocktails have shown benefits in both animal and clinical studies (Ahmed, 2012; Chan et al., 2008; Parachikova et al., 2010).”
MethodCotinine: A Potential New Therapeutic Agent against Alzheimer's disease
Echeverría, V., & Zeitlin, R. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00317.x · Cited by 86
Giommarelli, C., Zuco, V., Favini, E., Pisano, C., Piaz, F. D., Tommasi, N. D., & Zunino, F. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0233-x · Cited by 85
Kupershmidt, L., Amit, T., Bar-Am, O., Youdim, M. B. H., & Weinreb, O. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4279 · Cited by 85
Santa-Maria, I., Hernández, F., Del Rio, J., Moreno, F. J., & Avila, J. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-17 · Cited by 85
Skov, V., Glintborg, D., Knudsen, S., Tan, Q., Jensen, T., Kruse, T. A., Beck-Nielsen, H., & Højlund, K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002466 · Cited by 84
Cotinine Reduces Amyloid-β Aggregation and Improves Memory in Alzheimer's Disease Mice
Echeverria, V., Zeitlin, R., Burgess, S., Patel, S., Barman, A., Thakur, G., Mamcarz, M., Wang, L., Sattelle, D. B., Kirschner, D. A., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-102136 · Cited by 84
Buxbaum, J. D. (2002) · Frontiers in Bioscience · doi:10.2741/a739 · Cited by 82
Ni, R., Marutle, A., & Nordberg, A. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121447 · Cited by 82
Hellström‐Lindahl, E., Moore, H., & Nordberg, A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740777.x · Cited by 81
Padala, K. P., Padala, P. R., McNeilly, D. P., Geske, J., Sullivan, D. H., & POTTER, J. F. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.08.002 · Cited by 81
Gene Vaccination to Bias the Immune Response to Amyloid-β Peptide as Therapy for Alzheimer Disease
Qu, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1859 · Cited by 81
Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
A. Lasagna-Reeves, C., L. Castillo-Carranza, D., R. Jackson, G., & Kayed, R. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717177 · Cited by 80
Maskell, P. D., Speder, P., Newberry, N. R., & Bermudez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 80
The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation
Merla, R., Ye, Y., Lin, Y., Manickavasagam, S., Huang, M.-H., Perez‐Polo, R. J., Uretsky, B. F., & Birnbaum, Y. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00416.2007 · Cited by 80
Shen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79 · cited 2×
“03140, velusetrag, TD-8954, RQ-00000009, SUVN-D1003019 and SUVN-1004028 have shown cognitive benefits in preclinical studies with potential effects on amyloid processing (Shen et al., 2011).”
BackgroundNon-cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase
Zhang, H., Yan, H., & Tang, X. C. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9163-z · Cited by 79
Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease
Siedlak, S. L., Casadesus, G., Webber, K. M., Pappolla, M. A., Atwood, C. S., Smith, M. A., & Perry, G. (2009) · Free Radical Research · doi:10.1080/10715760802644694 · Cited by 78
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds355 · Cited by 78
Lipton, S. A., & Chen, H.-S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401344 · Cited by 77
Cabrol, C., Huzarska, M. A., Dinolfo, C., Rodriguez, M. C., Reinstatler, L., Ni, J., Yeh, L.-A., Cuny, G. D., Stein, R. L., Selkoe, D. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005274 · Cited by 76
?7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Neuroprotective, Neurotrophic or Both?
(2012) · Current Drug Targets · doi:10.2174/138945012800398973 · Cited by 75
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease
Fu, A. L., Zhou, C. Y., & Chen, X. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.020 · Cited by 75
Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice
Qu, B., Boyer, P. J., Johnston, S. A., Hynan, L. S., & Rosenberg, R. N. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.02.006 · Cited by 75
Plasma Gelsolin is Decreased and Correlates with Rate of Decline in Alzheimer's Disease
Güntert, A., Campbell, J., Saleem, M., O'Brien, D. P., Thompson, A. J., Byers, H. L., Ward, M. A., & Lovestone, S. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100279 · Cited by 74
Gahete, M. D., Rubio, A., Durán-Prado, M., Avila, J., Luque, R. M., & Castaño, J. P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1385 · Cited by 74
Capsoni, S., Marinelli, S., Ceci, M., Vignone, D., Amato, G., Malerba, F., Paoletti, F., Meli, G., Viegi, A., Pavone, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037555 · Cited by 74
Why Did Tarenflurbil Fail in Alzheimer's Disease?
Imbimbo, B. P. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1092 · Cited by 73
Vitamin E bioavailability in humans
Lodge, J. K. (2005) · Journal of Plant Physiology · doi:10.1016/j.jplph.2005.04.012 · Cited by 73
Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy
Maelicke, A., Hoeffle-Maas, A., Ludwig, J., Maus, A. D. J., Samochocki, M., Jordis, U., & Koepke, A. K. E. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9269-5 · Cited by 73
Chien, W., Liang, K., Teng, C., Kuo, S., Lee, F., & Fu, W. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1322 · Cited by 73
Enhancement of learning behaviour by a potent nitric oxide‐guanylate cyclase activator YC‐1
Chien, W., Liang, K., Teng, C., Kuo, S., Lee, F., & Fu, W. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03993.x · Cited by 72
Parnetti, L., Amici, S., Lanari, A., Romani, C., Antognelli, C., Andreasen, N., Minthon, L., Davidsson, P., Pottel, H., Blennow, K., et al. (2002) · Neurological Sciences · doi:10.1007/s100720200086 · Cited by 72
Schaeffer, E. L., Forlenza, O. V., & Gattaz, W. F. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1351-0 · Cited by 71 · cited 2×
“A2 is also suggested as a strategy for cognitive enhancement in AD (Schaeffer et al., 2009).”
BackgroundCortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease
Ikonomovic, M. D., Wecker, L., Abrahamson, E. E., Wuu, J., Counts, S. E., Ginsberg, S. D., Mufson, E. J., & DeKosky, S. T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.46 · Cited by 71
Sigma receptor modulators: a patent review
Collina, S., Gaggeri, R., Marra, A., Bassi, A., Negrinotti, S., Negri, F., & Rossi, D. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.769522 · Cited by 70
Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer’s disease
Chauhan, V. P. S., Ji, L., & Chauhan, A. (2008) · Biogerontology · doi:10.1007/s10522-008-9169-z · Cited by 69
Nathan, P. J., Boardley, R., Scott, N. E., Berges, A., Maruff, P. T., Sivananthan, T., Upton, N., Lowy, M. T., Nestor, P. J., & Lai, R. Y. K. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030003 · Cited by 69
Scott, L. E., Telpoukhovskaia, M., Rodríguez-Rodríguez, C., Merkel, M., Bowen, M. L., Page, B. D. G., Green, D. E., Storr, T., Thomas, F., Allen, D. D., et al. (2011) · Chem. Sci. · doi:10.1039/c0sc00544d · Cited by 68
Jones, R. W. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt49 · Cited by 68
Nelson, C., Wengreen, H. J., Munger, R. G., & Corcoran, C. D. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0249-9 · Cited by 67
Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, C. D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.015 · Cited by 67
Parri, H., & Dineley, K. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274464 · Cited by 67
ROSS, J., Brough, D., Gibson, R. M., Loddick, S. A., & Rothwell, N. J. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.015 · Cited by 66
Nicotinic receptor agonists and antagonists increase sAPPα secretion and decrease Aβ levels in vitro
Mousavi, M. T., & Hellström‐Lindahl, E. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.001 · Cited by 65
From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Okun, I., Tkachenko, S., Khvat, A., Mitkin, O., Kazey, V., & Ivachtchenko, A. (2010) · Current Alzheimer Research · doi:10.2174/156720510790691100 · Cited by 65
Cornelius, C., Fastbom, J., Winblad, B., & Viitanen, M. (2004) · Neuroepidemiology · doi:10.1159/000075957 · Cited by 64
Hsp90 Modulation for the Treatment of Alzheimer’s Disease
Zhao, H., Michaelis, M. L., & Blagg, B. S. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00001-5 · Cited by 63
Early-life events may trigger biochemical pathways for Alzheimer’s disease: the “LEARn” model
Lahiri, D. K., Zawia, N. H., Greig, N. H., Sambamurti, K., & Maloney, B. (2008) · Biogerontology · doi:10.1007/s10522-008-9162-6 · Cited by 62
Saumier, D., Duong, A., Haine, D., Garceau, D., & Sampalis, J. S. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0217-4 · Cited by 62
The interaction between methylene blue and the cholinergic system
Pfaffendorf, M., Bruning, T. A., Batink, H. D., & Van Zwieten, P. A. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701355 · Cited by 62
NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)
Gozes, I., Divinski, I., & Piltzer, I. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s3 · Cited by 61
Leyva, M. J., DeGiacomo, F., Kaltenbach, L. S., Holcomb, J., Zhang, N., Gafni, J., Park, H., Lo, D. C., Salvesen, G. S., Ellerby, L., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.014 · Cited by 60
Wang, T., Wang, C.-Y., Shan, Z.-Y., Teng, W.-P., & Wang, Z.-Y. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111874 · Cited by 59
Immunotherapy against amyloid pathology in Alzheimer's disease
Galimberti, D., Ghezzi, L., & Scarpini, E. A. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.013 · Cited by 58
Jia, J., Zhao, Q., Liu, Y., Gui, Y., Liu, G., Zhu, D., Yu, C., & Hong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.7 · Cited by 58
Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
Dysken, M. W., Guarino, P. D., Vertrees, J. E., Asthana, S., Sano, M., Llorente, M., Pallaki, M., Love, S., Schellenberg, G. D., McCarten, J. R., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.014 · Cited by 58
Medhurst, A. D., Roberts, J., Lee, J., Chen, C., Brown, S., Roman, S. A., & Lai, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00075.x · Cited by 57
NAP (Davunetide) Provides Functional and Structural Neuroprotection
Gozes, I. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795589373 · Cited by 57
Reproductive Hormones Modulate Oxidative Stress in Alzheimer's Disease
Barron, A. M., Fuller, S. J., Verdile, G., & Martins, R. N. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.2047 · Cited by 56
STUDIES ON THE METABOLISM OF (-)-COTININE IN THE HUMAN
Bowman, E. R., & McKennis, H. (1962) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26236-x · Cited by 55
Nitric oxide pathway is an important modulator of heat loss in rats during exercise
Lacerda, A. C. R., Marubayashi, U., & Coimbra, C. C. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.06.002 · Cited by 55
Hellweg, R., Wirth, Y., Janetzky, W., & Hartmann, S. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2766 · Cited by 54
Muayqil, T. A., & Camicioli, R. M. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000343479 · Cited by 54
Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging
Blalock, E. M., Phelps, J. T., Pancani, T., Searcy, J. L., Anderson, K. L., Gant, J. C., Popović, J., Avdiushko, M. G., Cohen, D. A., Chen, K.-C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010405 · Cited by 54
Nerve Growth Factor Treatment in Dementia
Jönhagen, M. E. (2000) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200000001-00006 · Cited by 53
Dockens, R. C., Wang, J.-S., Castaneda, L., Sverdlov, O., Huang, S., Slemmon, R., Gu, H., Wong, O. T., Li, H., Berman, R., et al. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0005-x · Cited by 53
Fjord‐Larsen, L., Kusk, P., Emerich, D. F., Thanos, C., Torp, M., Bintz, B. E., Tornøe, J., Johnsen, A. H., & Wahlberg, L. U. (2011) · Gene Therapy · doi:10.1038/gt.2011.178 · Cited by 53
Lagostena, L., Rosato-Siri, M., D'Onofrio, M., Brandi, R., Arisi, I., Capsoni, S., Franzot, J., Cattaneo, A., & Cherubini, E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3326-09.2010 · Cited by 52
Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Rosenmann, H. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030001 · Cited by 51
Aβ42-Binding Peptoids as Amyloid Aggregation Inhibitors and Detection Ligands
Luo, Y., Vali, S., Sun, S., Chen, X., Liang, X., Drozhzhina, T., Александровна, П. Е., & Борисович, Б. И. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400011f · Cited by 50
Liu, B., Frost, J. L., Sun, J., Fu, H., Grimes, S., Blackburn, P., & Lemere, C. A. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5924-12.2013 · Cited by 50
Yun, Y. U. E., Hu, L., Qin-jie, T. I. A. N., JIANG, J.-M., Yi-long, D. O. N. G., Jin, Z., CHENG, Y.-H., Hong, X., Ge, Q.-S., & Ping-ping, Z. U. O. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00618.x · Cited by 50
Allegri, R., & Guekht, A. B. (2012) · Drugs of today · doi:10.1358/dot.2012.48(suppl.a).1739721 · Cited by 49
The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?☆
Lee, J., Boo, J. H., & Ryu, H. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.016 · Cited by 49
Differential effects of statins and alendronate on cholinesterases in serum and brain of rats
Cibičková, Ľ., Palička, V., Cibicek, N., Čermáková, E., Mičuda, S., Bartošová, L., & Jun, D. (2007) · Physiological Research · doi:10.33549/physiolres.931121 · Cited by 49
Leszek, J., Inglot, A. D., Janusz, M., Byczkiewicz, F., Kiejna, A., Georgiades, J. A., & Lisowski, J. (2002) · PubMed · Cited by 47
Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease
Hung, C. H.-L., Ho, J. Y. S., & Chang, R. C. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.05.003 · Cited by 47
Neurotrophic Factors in Neurodegenerative Disorders: Potential for Therapy
Fumagalli, F., Molteni, R., Calabrese, F., Maj, P. F., Racagni, G., & Riva, M. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00004 · Cited by 46
Ahmed, H. H. (2010) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.11.012 · Cited by 45
Kozikowski, A. P., Chen, Y., Subhasish, T., Lewin, N. E., Blumberg, P. M., Zhong, Z., D'Annibale, M. A., Wang, W., Shen, Y., & Langley, B. (2009) · ChemMedChem · doi:10.1002/cmdc.200900045 · Cited by 44
Gravius, A., Laszy, J., Pietraszek, M., Sághy, K., Nagel, J., Chambon, C., Wegener, N., Valastro, B., Danysz, W., & Gyertyán, I. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328343d804 · Cited by 43
Anisuzzaman, A. S. M., Uwada, J., Masuoka, T., Yoshiki, H., Nishio, M., Ikegaya, Y., Takahashi, N., Matsuki, N., Fujibayashi, Y., Yonekura, Y., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12306 · Cited by 41
The Memantine Lombardy Study Group, Clerici, F., Vanacore, N., Elia, A., Alegiani, S. S., Pomati, S., Cas, R. D., Raschetti, R., & Mariani, C. B. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0618-0 · Cited by 41
Janusz, M., & Zabłocka, A. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162377 · Cited by 41
Cerebrolysin in Alzheimer's disease
Alvarez, X. A., & Fuentes, P. (2011) · Drugs of today · doi:10.1358/dot.2011.47.7.1656496 · Cited by 41
HILLER, K. ‐., & Asmus, K. D. (1981) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008114551581 · Cited by 40
Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease
Shimohama, S., Sasaki, Y., Fujimoto, S., Kamiya, S., Taniguchi, T., Takenawa, T., & Kimura, J. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00342-4 · Cited by 40
Sala, S. G., Muñoz, Ú., Bartolomé, F. B., Bermejo, F., & Martín‐Requero, Á. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.128959 · Cited by 40
Marazziti, D., Baroni, S., Pirone, A., Giannaccini, G., Betti, L., Schmid, L., Vatteroni, E., Palego, L., Borsini, F., Bordi, F., et al. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0684-y · Cited by 39
Klugman, A., Naughton, D. P., Isaac, M. G. E. K. N., Shah, I., Petróczi, A., & Tabet, N. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120124 · Cited by 39
Protective effect of lutein against benzo(a)pyrene-induced oxidative stress in human erythrocytes
VijayaPadma, V., Ramyaa, P., Pavithra, D., & Krishnasamy, R. (2012) · Toxicology and Industrial Health · doi:10.1177/0748233712457439 · Cited by 38
Lichtenstein, M. P., Carriba, P., Baltrons, M. A., Wójciak‐Stothard, B., Peterson, J. R., García, A., & Galea, E. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101332 · Cited by 36
H2O2 and PAF mediate Aβ1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761
Shi, C., Wu, F., & Xu, J. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.03.016 · Cited by 36
Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism
Masilamoni, J. G., Philip, J. E., Ashok, B. S., Kirubagaran, R., Walter, C. E. J., Dicky John Davis, G., Vignesh, S., Dhandayuthapani, S., & Rajadas, J. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.011 · Cited by 36
Buxbaum, J. D. (2002) · Frontiers in bioscience · doi:10.2741/buxbaum · Cited by 36
Miguel-Hidalgo, J. J., Paul, I. A., Wanzo, V., & Banerjee, P. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.032 · Cited by 35
Frontiers in Alzheimer’s disease therapeutics
Stone, J. G., Casadesús, G., Rothenberg, K. G., Siedlak, S. L., Wang, X., Zhu, X., Perry, G. L., Castellani, R. J., & Smith, M. A. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310382817 · Cited by 35
Wright, T. M. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.5.973584 · Cited by 35
Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34
Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F., & Gunay, I. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100875 · Cited by 34
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 33
Niva, C., PARKINSON, J. R., Olsson, F., van Schaick, E., Lundkvist, J., & Visser, S. A. G. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1459-3 · Cited by 33
Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat
Cavas, M., & Navarro, J. F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.06.013 · Cited by 33
Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein
Schaeffer, E. L., de Paula, V. D. J. R., Aquino, E. R. D. S., Novaes, B. D. A., Skaf, H. D., Forlenza, O. V., & Gattaz, W. F. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0619-4 · Cited by 29
Yu, Q., Reale, M., Kamal, M. A., Holloway, H. W., Luo, W., Sambamurti, K., Ray, B., Lahiri, D. K., Rogers, J. T., & Greig, N. H. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312020003 · Cited by 29
The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials
Mohs, R. C. (2004) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00112.x · Cited by 28
Patat, A. A., Parks, V., Raje, S. V., Plotka, A., Chassard, D., & Coz, F. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03348.x · Cited by 28
Motawaj, M., Burban, A., Davenas, E., & Arrang, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174458 · Cited by 28
Mozayan, M., & Lee, T. J.-F. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00269.2007 · Cited by 28
Nakaya, K., Nakagawasai, O., Arai, Y., Onogi, H., Sato, A., Niijima, F., Tan–No, K., & Tadano, T. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.053 · Cited by 26
Ovine colostrum nanopeptide affects amyloid beta aggregation
Janusz, M., Woszczyna, M., Lisowski, M., Kubis-Kubiak, A., Macała, J., Gotszalk, T. P., & Lisowski, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.11.053 · Cited by 26
Therapeutic potential of histamine H3 receptor antagonists in dementias
Chazot, P. L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.2.1475899 · Cited by 26
Long, D. D., Armstrong, S. R., Beattie, D. T., Choi, S. K., Fatheree, P. R., Gendron, R. A. L., Genov, D. G., Goldblum, A. A., Humphrey, P. P. A., Jiang, L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.051 · Cited by 25
Lee, R. H., Tseng, T.-Y., Wu, C. Y., Chen, P., Chen, M., Kuo, J., & Lee, T. J.-F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040326 · Cited by 25
Novel Penetrating Cations for Targeting Mitochondria
Chernyak, B. V., Antonenko, Y. N., Domnina, L. V., Ivanova, O. Y., Lyamzaev, K. G., Pustovidko, A. V., Rokitskaya, T. I., Severina, I. I., Simonyan, R. A., Trendeleva, T. A., et al. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319150015 · Cited by 25
Webster, S. J., Mruthinti, S., Hill, W. D., Buccafusco, J. J., & Terry, A. V. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8176-z · Cited by 23
Effect of nitric oxide synthase inhibitors on short-term appetite and food intake in humans
Vozzo, R., Wittert, G., Horowitz, M., Morley, J. E., & Chapman, I. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.6.r1562 · Cited by 23
Differential Chromosome Sensitivity to 5-Azacytidine in Alzheimer’s Disease
Marques Payão, S. L., de Arruda Cardoso Smith, M., & Ferreira Bertolucci, P. H. (1998) · Gerontology · doi:10.1159/000022023 · Cited by 22
Gabaergic Drugs and Alzheimer’s Disease
Limón, A., Reyes‐Ruiz, J. M., & Miledi, R. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.10.291 · Cited by 21
Nitric Oxide Synthase 3-Mediated Neurodegeneration After Intracerebral Gene Delivery
de la Monte, S. M., Jhaveri, A. P., Maron, B. A., & Wands, J. R. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318040cfa2 · Cited by 21
Othman, A. A., Haig, G. M., Florian, H., Locke, C. S., Zhang, J., & Dutta, S. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04472.x · Cited by 20
A meta-analysis of mood stabilizers for Alzheimer’s disease
Xiao, H., Su, Y., Cao, X., Sun, S., & Liang, Z. (2010) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-010-0559-5 · Cited by 19
Ringman, J. M., Cole, G. M., Teng, E., Badmaev, V., Bardens, J., Frautschy, S. A., Rosario, E. R., Fein, J., Porter, V. R., Vanek, Z. F., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2414 · Cited by 19
Moss, D. E., Fariello, R. G., Sahlmann, J., Sumaya, I. C., Pericle, F., & Braglia, E. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12018 · Cited by 18
Jing-ying, Jia, J., Qian‐Hua, Zhao, Yun, Y., Liu, YuZHOU, Gang-yi, Dayuan, Zhu, et al. (2013) · 中国药理学报:英文版 · Cited by 17
Storozhevykh, T. P., Senilova, Y. E., Brustovetsky, T., Pinelis, V. G., & Brustovetsky, N. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0058-x · Cited by 16
O1‐04‐03: The ADCS valproate neuroprotection trial: Primary efficacy and safety results
Tariot, P. N., Aisen, P. S. S., Cummings, J. L., Jakimovich, L. J., Schneider, L. S. S., Thomas, R. G., Becerra, L. M., & Loy, R. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.216 · Cited by 16
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
Salehi, B., Machin, L., Monzote, L., Sharifi-Rad, J., Ezzat, S. M., Salem, M. A., Merghany, R. M., El Mahdy, N. M., Kılıç, C. S., Sytar, O., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01818 · Cited by 707
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Metadata
- Authors
- Anand, R., Gill, K. D., & Mahdi, A. A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 76
- Pages
- 27-50
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2003109394
- Cited by
- 747
- References
- 406
- FWCI
- 27.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.